Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the worst performer among all 11 sectors of the S&P 500 in 2026. While that has ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a ...

Hims & Hers Health, Inc. HIMS is scheduled to report fourth-quarter 2025 results on Feb. 23, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 6 cents ...

Bear Concerns: Validated or Busted? 1. GLP-1 regulatory risk. Validated. U.S. revenue declined 8% YoY on the pivot from compounded GLP-1s, with $33.49 million in restructuring charges. 2. Margin ...

Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and ...

Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.